Back to Authors

Patnaik, Mrinal M.

https://orcid.org/0000-0001-6998-662X

A5072463255 | I1330342723

Mayo Clinic

Citations 648

Novel Disease-Causing Mutations in UBA1 Reveal Disease Mechanisms in Bone Marrow Failure and Inflammation

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2914-2915

10.1182/blood-2022-168031

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9675-9676

10.1182/blood-2022-163485

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12353-12354

10.1182/blood-2022-155561

Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6872-6873

10.1182/blood-2022-167720

Differential Impact on Survival in Myeloid Neoplasm Patients with U2AF1 Mutations

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9602-9603

10.1182/blood-2022-167405

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9798-9799

10.1182/blood-2022-165859

Clonal Hematopoiesis in Vexas Syndrome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 5745-5746

10.1182/blood-2022-160263

Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6309-6311

10.1182/blood-2022-164769

Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9019-9020

10.1182/blood-2022-168303

Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1286-1287

10.1182/blood-2022-165491